drugset / Trial / NCT05214690
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2
RandomizedCrossoverOpen-labelTreatment
Summary
Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study
Timeline
- Start
- 2020-08-13
- Primary completion
- 2020-09-08
- Completion
- 2020-09-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pelubiprofen | Small molecule | 25 mg | Oral |
| Subject | Pelubiprofen | Small molecule | 30 mg | Oral |